CQ3196

CQ3196 is an orally active RIOK2 inhibitor with a Kd of 14 nM. CQ3196 effectively inhibits the ATPase activity of RIOK2, with an IC50 value of 72 nM. CQ3196 inhibits cell proliferation and colony formation in gastric cancer cell lines. CQ3196 induces cell apoptosis in HGC-27 and AGS cells. CQ3196 suppresses downstream signal pathway of RIOK2. CQ3196 reduces phosphorylation of mTOR and AKT. CQ3196 modulates ribosome function and protein synthesis. CQ3196 inhibits tumor growth and can be used for gastric cancer invtro and invivo research[1].

Product Specifications

CAS Number

[3105591-09-8]

UNSPSC

12352005

Target

Apoptosis; Ser/Thr Kinase

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

COC1=CC=C(C=N1)C2=CC=C3N=C(C4=C(N(N=N4)C5=CC=C(C(C(F)(F)F)=C5)N6CCC(N(C)C)CC6)C3=C2)OC

Molecular Formula

C30H30F3N7O2

Molecular Weight

577.60

References & Citations

[1]Ma H, et al. Design, Synthesis and Evaluation of 4-Methoxy-1H-[1,2,3]triazolo[4,5-c]quinolines as Highly Potent and Oral Available RIOK2 Inhibitors. J Med Chem. 2025 Aug 28;68 (16) :17774-17793.